Last updated August 21, 2024
The below chart shows quarterly revenue of select anti-obesity medications, as well as the total market size for novel anti-obesity drugs.
Click a bar on the chart to see more detail on quarterly revenue and commercial opportunity.
To show or hide bars, click the legend.
Data from SEC filings and company websites. Semaglutide revenue is reported in DKK and converted to USD based on the average DKK:USD conversion rate for the quarter from the Federal Reserve Bank of St. Louis.
Data are collected with a combination of automated data collection (including use of AI) and manual review. Data may be inaccurate.